It is expected that the new HCM drug Camzyos will be commercialized in Korea. According to related industries, BMS Pharmaceutical Korea recently submitted an application to the Ministry of Food and Drug Safety for permission for the NYHA Class 2-3 (class II-III) HCM treatment Camzyos. Camzyos is acquired by BMS for $13.1 billion in 2020 and is a PO drug that targets and inhibits cardiac myosin for functional treatment and symptom improvement of HCM. Camzyos, which was approved by the U.S. FDA in April, is the first and only cardiac myosin inhibitor targeting the source of obstructive hypertrophic cardiomyopathy and has a mechanism to reduce heart muscle contractility and left ventricular hypertrophy by inhibiting the